Analystreport

TapImmune Inc (NASDAQ: MRKR) is now covered by analysts at Nomura. They set a "buy" rating and a $16.00 price target on the stock.

Marker Therapeutics, Inc.  (MRKR) 
Last marker therapeutics, inc. earnings: 11/12 04:01 pm Check Earnings Report